Monoclonal antibodies with broad reactivity against antigens on the parasite that causes malaria, Plasmodium falciparum, are isolated from two subjects and are found to have an unusual insertion of an immunoglobulin-like domain from a different chromosome, illustrating a new mechanism of antibody diversification. This paper reports the isolation of monoclonal antibodies with broad reactivity against Plasmodium falciparum antigens from two subjects living in a malaria-endemic region in Kilifi, Kenya. The antibodies are unusual in that they carry large insertions of an immunoglobulin-like domain from LAIR1, an Ig superfamily inhibitory receptor encoded on chromosome 19. The antibodies bind to polymorphic surface antigens on the parasite surface; binding depends on the mutated form of the insert. These findings illustrate a novel mechanism of antibody diversification, and the existence of conserved epitopes that may be suitable candidates for the development of a malaria vaccine. Plasmodium falciparum antigens expressed on the surface of infected erythrocytes are important targets of naturally acquired immunity against malaria, but their high number and variability provide the pathogen with a powerful means of escape from host antibodies1,2,3,4. Although broadly reactive antibodies against these antigens could be useful as therapeutics and in vaccine design, their identification has proven elusive. Here we report the isolation of human monoclonal antibodies that recognize erythrocytes infected by different P. falciparum isolates and opsonize these cells by binding to members of the RIFIN family. These antibodies acquired broad reactivity through a novel mechanism of insertion of a large DNA fragment between the V and DJ segments. The insert, which is both necessary and sufficient for binding to RIFINs, encodes the entire 98 amino acid collagen-binding domain of LAIR1, an immunoglobulin superfamily inhibitory receptor encoded on chromosome 19. In each of the two donors studied, the antibodies are produced by a single expanded B-cell clone and carry distinct somatic mutations in the LAIR1 domain that abolish binding to collagen and increase binding to infected erythrocytes. These findings illustrate, with a biologically relevant example, a novel mechanism of antibody diversification by interchromosomal DNA transposition and demonstrate the existence of conserved epitopes that may be suitable candidates for the development of a malaria vaccine.
Up to 10% of individuals in malaria-endemic regions produce antibodies that react to malaria antigens through an additional LAIR1 domain that is inserted by two different insertion modalities. Antonio Lanzavecchia and colleagues show that in malaria endemic regions, 5% to 10% of exposed individuals have antibodies directed against a type of variant antigen expressed on the surface of cells infected with Plasmodium falciparum that have an insertion of the LAIR1 domain. For comparison, less than 0.01% of the European blood donors showed very low levels of such antibodies. Insertion of templated DNA into either the VDJ or IgH switch region of the antibody generates antibodies with two distinct binding specificities and represents an additional mechanism of antibody diversification. In two previously described donors, the extracellular domain of LAIR1, a collagen-binding inhibitory receptor encoded on chromosome 19 (ref. 1), was inserted between the V and DJ segments of an antibody. This insertion generated, through somatic mutations, broadly reactive antibodies against RIFINs, a type of variant antigen expressed on the surface of Plasmodium falciparum-infected erythrocytes2. To investigate how frequently such antibodies are produced in response to malaria infection, we screened plasma from two large cohorts of individuals living in malaria-endemic regions. Here we report that 5–10% of malaria-exposed individuals, but none of the European blood donors tested, have high levels of LAIR1-containing antibodies that dominate the response to infected erythrocytes without conferring enhanced protection against febrile malaria. By analysing the antibody-producing B cell clones at the protein, cDNA and gDNA levels, we characterized additional LAIR1 insertions between the V and DJ segments and discovered a second insertion modality whereby the LAIR1 exon encoding the extracellular domain and flanking intronic sequences are inserted into the switch region. By exon shuffling, this mechanism leads to the production of bispecific antibodies in which the LAIR1 domain is precisely positioned at the elbow between the VH and CH1 domains. Additionally, in one donor the genomic DNA encoding the VH and CH1 domains was deleted, leading to the production of a camel-like LAIR1-containing antibody. Sequencing of the switch regions of memory B cells from European blood donors revealed frequent templated inserts originating from transcribed genes that, in rare cases, comprised exons with orientations and frames compatible with expression. These results reveal different modalities of LAIR1 insertion that lead to public and dominant antibodies against infected erythrocytes and suggest that insertion of templated DNA represents an additional mechanism of antibody diversification that can be selected in the immune response against pathogens and exploited for B cell engineering.